Shopping Cart
- Remove All
- Your shopping cart is currently empty
Stamulumab (MYO-029), a recombinant human IgG1λ antibody, targets and neutralizes myostatin by inhibiting its interaction with the ActRIIB receptor, leading to muscle fiber hypertrophy rather than hyperplasia in SCID mice. This compound shows research potential for treating disorders such as Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) [1] [2].
Description | Stamulumab (MYO-029), a recombinant human IgG1λ antibody, targets and neutralizes myostatin by inhibiting its interaction with the ActRIIB receptor, leading to muscle fiber hypertrophy rather than hyperplasia in SCID mice. This compound shows research potential for treating disorders such as Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) [1] [2]. |
Cas No. | 705287-60-1 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.